Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Kura Oncology (NASDAQ:KURA) had its target price upped by HC Wainwright from $32.00 to $37.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and lowered their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Up 7.4 %

Shares of KURA opened at $10.80 on Thursday. The business’s 50 day moving average is $17.88 and its 200 day moving average is $19.67. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $9.06 and a 12-month high of $24.17. The company has a market capitalization of $839.81 million, a PE ratio of -4.58 and a beta of 0.86.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Kura Oncology during the third quarter valued at $25,000. ProShare Advisors LLC lifted its holdings in Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC boosted its position in Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after buying an additional 1,673 shares during the period. The Manufacturers Life Insurance Company grew its stake in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.